shot-button
Ganesh Chaturthi Ganesh Chaturthi
Home > News > World News > Article > Third Covid 19 vax improves immunity in blood cancer patients Study

Third Covid-19 vax improves immunity in blood cancer patients: Study

Updated on: 27 March,2022 09:05 AM IST  |  London
Agencies |

Patients with lymphoma have defects in their immune system that restrict their response to vaccination

Third Covid-19 vax improves immunity in blood cancer patients: Study

Representation pic

The weakened immune systems of blood cancer patients can improve after they receive a third Covid-19 vaccination, finds a new study. 


Patients with lymphoma have defects in their immune system that restrict their response to vaccination.



Despite this, the new study found improvements in antibody and T-cell responses after a third vaccine dose, except in patients who had recently received a certain antibody treatment for their cancer. 


48,03,33,071
Total number of cases worldwide as of Saturday

61,44,279
Total no. of deaths worldwide

41,46,41,868
Patients Recovered worldwide as of Saturday

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!

Register for FREE
to continue reading !

This is not a paywall.
However, your registration helps us understand your preferences better and enables us to provide insightful and credible journalism for all our readers.

Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK